If you take a GLP-1 drug and have an operation booked, this is the study to know about. Across 119 UK hospitals and 47,039 patients, regurgitation or stomach contents entering the lungs happened to about 1 in 71 people taking a GLP-1 drug, against about 1 in 802 of everyone else. The events clustered at … Read more
Adolescents with obesity who started semaglutide, liraglutide or tirzepatide were less likely to have a recorded suicide-related event over up to three years than matched adolescents managed with lifestyle intervention, according to an electronic health records study published on 14 September in Diabetes, Obesity and Metabolism. It points away from psychiatric harm in the age … Read more
The European Association for the Study of Obesity has published a position statement whose argument is not about whether incretin drugs work. It treats that as settled. The argument is that everything around the prescription has failed to keep pace: patient selection, monitoring, clinician training and access have all moved more slowly than the drugs, … Read more
Between January 2021 and December 2025, Europe’s pharmacovigilance database logged 42,941 adverse-event reports naming liraglutide, semaglutide or tirzepatide as a suspect drug in diabetes or weight management. Of those, 225 involved suicide or self-injury: 141 for semaglutide, 47 for tirzepatide, 37 for liraglutide. A new analysis sets the three against each other and finds such … Read more
A meta-analysis of 32 randomised trials covering 40,408 people puts the average weight loss on GLP-1 and dual-agonist drugs at 9.36%. Most of the paper is about why that average hides so much. Trials enrolling people who also had type 2 diabetes, obstructive sleep apnoea or fatty liver disease reported systematically smaller losses. Trials that … Read more
Among adults who have both asthma and type 2 diabetes, starting tirzepatide rather than semaglutide made no difference to the chance of an asthma attack over a year. A US multicentre analysis of 16,352 matched patients, published on 7 September 2026, found that 11.0% of the tirzepatide group and 11.1% of the semaglutide group had … Read more
Between a quarter and a third of people who have bariatric surgery regain a significant amount of weight within two to five years, according to the figures cited by the authors of a new review. Their meta-analysis, published in Frontiers in Endocrinology, pulls together what is known about treating that regain with a GLP-1 drug … Read more
A meta-analysis of 19 randomised trials behind semaglutide, tirzepatide and liraglutide reports a gap between what those trials recorded and what their own bloodwork showed. Investigators logged malnutrition as an adverse event in 0.12% of participants. Laboratory screening in the same trials found abnormally low lymphocyte counts in 2.90% of people taking active drug, against … Read more